Restoring confidence in evidence: UK report calls for big changes

Around the world / 02 December 2017

Photo: Ousa Chea, Unsplash

The UK Academy of Medical Sciences recommends major changes in how medical research is managed and communicated and the importance of scientific evidence in decision making.


The disturbing discovery that only about one third of the UK population trusted medical evidence and that two-thirds relied on the opinions of friends and family as their preferred sources of information, runs through a major new report by the UK Academy of Medical Sciences. Recent controversies around the benefits and harms of treatments such as statins, hormone replacement therapy and Tamiflu also highlighted the need for action.

“Enhancing the use of scientific evidence to judge the potential benefits and harms

of medicines” was published in June this year. It is the result of ‘a project to examine how the generation, trustworthiness and communication of scientific evidence can be enhanced to strengthen its role in decisions by patients, carers, healthcare professionals and others about the benefits and harms of medicines.’ These are some of the headline proposals to address real and perceived weaknesses in medical research, evidence and their communication:

  • Involvement of patients, carers and the wider public in research
  • Enhanced training in research methods and use of statistics
  • Support for new study designs and new methodologies, such as health apps and wearable technologies
  • The provision of evidence that is accessible, assessable and usable by the intended audience
  • Frameworks in which researchers can declare and manage interests
  • Presentation of scientific evidence in a clear, accessible and usable way
  • Improvements in patient information leaflets to include a balanced and easily understandable appraisal of medicines
  • A ‘traffic light’ system for press releases indicating how likely the research is to improve clinical practice in the near future and the robustness of the research
  • Codes of practice for all generators and communicators of research evidence to convey accurate, assessable and balanced information to the public.

There is also a proposal that a single, reliable, high profile, go-to destination for clear, up-to-date and evidence-based information should be strongly promoted; in the UK, this would be the NHS Choices website.

Among the excellent materials accompanying the report are 90-second videos illustrating the main points, social media posts and beautifully designed short summary documents of major recommendations, including one that lists questions patients should ask their doctors when discussing their medicines, and an accessible 8-page summary version of the long and complex report.

A short summary like this does not do justice to the depth and significance of the issues being addressed, nor the reforms being proposed, but it is clear that implementation of the recommendations would have a radical effect on how research is conducted, how evidence is communicated, and how well patients and their health professionals are supported in making the best decisions about medicines. The presentation of the report and its accompanying materials are also fine examples of good communication practice in action.

Read more:

 

Bruce Hugman
Communications Consultant, UMC

You may also like


Developing a pharmacovigilance system in the Instituto Nacional de Cardiología Ignacio Chávez at Mexico City

Undaunted by the pandemic, the team at Instituto Nacional de Cardiología Ignacio Chávez (Mexico) established a PV centre and a follow-up unit with direct, daily clinical impact.

Around the world / 10 February 2022

Egypt’s counterfeit medicines: Going beyond the signal

One recent case involving a potentially dangerous fake antibiotic drug has brought to the fore systemic weaknesses that can only be remedied by group action.

Around the world / 14 July 2022

EMA module on pregnancy prevention programmes and other pregnancy-specific risk minimisation

EMA has launched a public consultation on a new guidance: the EU-GVP Module XVI ADD III on pregnancy and other pregnancy-specific risk minimisation.

Around the world / 29 April 2022

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more